35th week of 2010 patent applcation highlights part 40 |
Patent application number | Title | Published |
20100222201 | Cast Bodies, Castable Compositions, And Methods For Their Production - A low-water-content castable composition produces cast products with an increased modulus of rupture, an increased cold crushing strength, and decreased porosity. The composition employs closed fractions of constituent particles with specified populations and specified gaps in the particle size distribution to produce these properties. The composition is suitable for refractory applications. | 2010-09-02 |
20100222202 | TURNDOWN THERMOCOMPRESSOR DESIGN FOR CONTINUOUS CATALYST RECOVERY - Systems and processes for regenerating catalyst are provided herein that include a catalyst regeneration tower having a cooling zone that receives a catalyst cooling stream generated by a cooling gas loop. The systems and processes include a first thermocompressor that utilizes a first motive vapor and a second thermocompressor that utilizes a second motive vapor in order to provide the catalyst cooling stream to the regeneration tower. The second thermocompressor operates in parallel with the first thermocompressor. The first thermocompressor can utilize combustion air as the motive vapor. The second thermocompressor can utilize nitrogen as the motive vapor. | 2010-09-02 |
20100222203 | PRODUCTION METHOD FOR PROPYLENE, RESTORATION METHOD FOR CATALYST, AND SOLID ACID CATALYST - A production method for propylene is characterized in that ethanol is converted into propylene by continuously reacting ethanol on a catalyst. A solid acid catalyst is characterized in that the kinetic constant k of the butane cracking reaction on the catalyst at 500° C. is 0.1 to 30 (cm | 2010-09-02 |
20100222204 | METHOD OF PREPARING A CONTROLLED POROSITY GEOPOLYMER, THE RESULTING GEOPOLYMER AND THE VARIOUS APPLICATIONS THEREOF - The present invention relates to a method for preparing a controlled porosity geopolymer with a step of dissolution/polycondensation of an aluminosilicate source in an activation solution comprising the following successive steps: (a) defining a characteristic of the porosity of the geopolymer to be prepared; (b) determining a value or an element for a parameter chosen from the total amount of water, the total amount of silica, the compensation cation, and the particle size distribution of the optional silicate components, which makes it possible to obtain the characteristic defined in step (a); and (c) selecting said value or said element predetermined in step (b). The present invention relates to a geopolymer capable of being prepared by said method and also to the various uses of said geopolymer. | 2010-09-02 |
20100222205 | Method Of Manufacturing A Catalyst Body By Post-Impregation - A method of manufacturing a catalyst body which includes: combining one or more inorganic components with an inorganic binder, and optionally with an organic binder, to form a mixture, the one or more inorganic components comprising a primary phase material being zeolite, or CeO | 2010-09-02 |
20100222206 | METHOD FOR PRODUCTION OF ELECTRODE CATALYST FOR FUEL CELL - Disclosed is a method for producing an electrode catalyst for a fuel cell, which comprises a Ru-containing metal microparticle supported on an electrically conductive carbon carrier, wherein M | 2010-09-02 |
20100222207 | METHOD OF SYNTHESIZING SILICON CARBIDE MATERIALS FROM SILICON BASED POLYMERS - A method of synthesizing SiC materials comprising the step of making a blend which consists of a silicon based polymer and a metal complex by blending a silicon based polymer solution and a metal complex solution and drying, and firing the blend in an inert gas at 700° C. or more; and a SiC ceramic material which has catalyst performance in which a CO gas is oxidized to generate a CO | 2010-09-02 |
20100222208 | OH-TYPE ANION-EXCHANGE HYDROCARBON-BASED ELASTOMER, USE AND PRODUCTION METHOD THEREOF - The present invention aims at providing an optimal constitution and production method for an OH-type anion-exchange hydrocarbon-based elastomer used when manufacturing a catalyst electrode layer of a solid polymer type fuel cell, in view of a balance of stability, durability and flexibility. Also, the present invention aims to provide an ion-conductivity imparting agent comprising the OH-type anion-exchange hydrocarbon-based elastomer, wherein the elastomer is uniformly dissolved or dispersed and has appropriate viscosity even with a high concentration. | 2010-09-02 |
20100222209 | USE OF SHAPED BODIES HAVING CATALYTIC PROPERTIES AS REACTOR INTERNALS - The invention relates to moulded bodies having catalytic properties, obtained due to a method that comprises the following said steps: a) a moulded body is produced by means of a powder-based rapid-prototyping-method, b) said moulded body is optionally heat-treated, c) at least one catalytically active component is optionally applied to the moulded body, d) said moulded body is optionally subjected to another heat-treatment. The steps b, c) and/or d) can be performed several times. Said moulded bodies are used as reactor fittings in heterogeneously catalyzed chemical reactions. | 2010-09-02 |
20100222210 | CATALYSTS AND PROCESSES FOR SELECTIVE HYDROGENATION OF ACETYLENE AND DIENES IN LIGHT OLEFIN FEEDSTREAMS - A catalyst and a method for selective hydrogenation of acetylene and dienes in light olefin feedstreams are provided. The catalyst retains higher activity and selectivity after regeneration than conventional selective hydrogenation catalysts. The catalyst contains a first component and a second component supported on an inorganic support. The inorganic support contains at least one salt or oxide of zirconium, a lanthanide, or an alkaline earth. | 2010-09-02 |
20100222211 | Compositions of nanoparticles on solid surfaces - A method for producing nanoparticles on a substrate using a metal precursor in an ionic liquid and microwave heating is described. The composite compositions are useful as catalysts for chemical reactions, fuel cell, supercapacitor and battery components, and the like. | 2010-09-02 |
20100222212 | Production Of Chain Agglomerations Of Nano-Scale Metal Particles - A process and apparatus for producing chain agglomerations of nano-scale metal particles includes feeding at least one decomposable moiety selected from the group consisting of organometallic compounds, metal complexes, metal coordination compounds and mixtures thereof into a reactor vessel; exposing the decomposable moiety to a source of energy sufficient to decompose the moiety and produce nano-scale metal particles; and deposit or collection of chain agglomerations of nano-scale metal particles. | 2010-09-02 |
20100222213 | HONEYCOMB STRUCTURE - A honeycomb structure includes aluminum titanate, cell walls, and pore portions. The cell walls extend along a longitudinal direction of the honeycomb structure to define cells between the cell walls. The pore portions have an average pore diameter of about 10 μm to about 20 μm. A length of a longest pore portion among the pore portions in a binary image including substrate portions and the pore portions is about 8 times or less of the average pore diameter. The binary image is converted from a microscopic image of a cross section of the cell walls in parallel with the longitudinal direction. The length is measured along a line drawn in a direction perpendicular to a thickness direction of the cell walls. | 2010-09-02 |
20100222214 | Production Of Chain Agglomerations Of Nano-Scale Metal Particles - A process and apparatus for producing chain agglomerations of nano-scale metal particles includes feeding at least one decomposable moiety selected from the group consisting of organometallic compounds, metal complexes, metal coordination compounds and mixtures thereof into a reactor vessel; exposing the decomposable moiety to a source of energy sufficient to decompose the moiety and produce nano-scale metal particles; and deposit or collection of chain agglomerations of nano-scale metal particles. | 2010-09-02 |
20100222215 | HALIDE SCAVENGERS FOR HIGH TEMPERATURE APPLICATIONS - A composite sorbent is formed which is the reaction product of a solid alkali metal carbonate, rehydratable alumina and water or an aqueous solution of a metal salt. The reaction between the components occurs while forming particulates followed by curing and activation at high temperatures. The alkali metal in the sorbent exhibits a highly reactive and accessible state that is very favorable for various sorption applications. The sorbent is especially useful for removal of HCl and other acid contaminants from gas and liquid hydrocarbon streams at high temperatures. | 2010-09-02 |
20100222216 | METAL HONEYCOMB-SHAPED CATALYZER CARRIER - In a metal honeycomb-shaped catalyzer carrier | 2010-09-02 |
20100222217 | Fungicidal N-[2-(Haloalkoxy)Phenyl]Heteroarylcarboxamides - N-[2-(Haloalkoxy)phenyl]heteroarylcarboxamides of the formula I, where n=0 or 1, Hal=halogen, X=C | 2010-09-02 |
20100222218 | INSECTICIDAL HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES - The invention relates to the use of heterocyclic carboxylic acid derivatives of the formula (I) below | 2010-09-02 |
20100222219 | Thiophene-Sulphonic Acid Picolyl Amides - The present invention relates to thiophene-sulfonic acid picolyl amides of the Formula (I), where R | 2010-09-02 |
20100222220 | COMPOSITIONS OF PARTICULATE COFORMULATION - Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface is an additive-rich surface without a distinct physical boundary between the particle center and the particle surface. The relative additive concentration may have a continuous rate of change across the finite gradient. In some examples, an active substance:additive ratio of the particle surface is sufficiently low to form a protective surface layer around the active substance. Generally, the particle surface is free of the active substance. | 2010-09-02 |
20100222221 | N-ALKOXYAMIDES OF 6-(TRISUBSTITUTED PHENYL)-4-AMINOPICOLINATES AND THEIR USE AS SELECTIVE HERBICIDES FOR CROPS - N-Alkoxyamides of 4-aminopicolinic acids and 6-amino-4-pyrimidinecarboxylates are selective herbicides for corn, canola and sugar beet. | 2010-09-02 |
20100222222 | COMPOSITE SUPERCONDUCTOR - Disclosed is a composite superconductor comprising a superconductor and a metal member. The metal member is composed of one or more members to be joined together in such manner that the one or more members cover the superconductor, and at least one member is made of aluminum or an aluminum alloy. | 2010-09-02 |
20100222223 | METHOD FOR ASSAYING SEPSIS IN HUMANS - The present invention relates to a reliable method of prediction of sepsis in humans after a trauma, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development of sepsis at early stages of the disease. Furthermore a method of determination of PSP/reg levels in serum is described. | 2010-09-02 |
20100222224 | Bioelectronic tongue for food allergy detection - The present invention is directed to a method and apparatus that satisfies the need for a bioelectronic tongue for food allergy detection. The method of detecting concentration of food allergen incorporates antibodies into an electronic tongue to create a bioelectronic tongue. Additionally the method uses impedance, capacitance, and/or other related electrochemical methods for detecting analyte in complex media. Furthermore the method additionally includes methods to subtract out non-specific interactions. The method also subtracts non-specific interactions. The device/apparatus is a Bioelectronic Tongue for detecting allergen in diluted food samples. The device includes: a sensor array; an impedance or capacitance analyzer; a preprocessor; a feature extractor; a pattern recognizer; and an output device indicating an allergen concentration. In order to implement the method of detecting food allergens on a bioelectronic tongue a computer readable medium containing an executable program is used for performing the analysis of a food sample. The executable program performs the acts of: preprocessing data from an impedance analyzer; extracting a feature pattern; recognizing a pattern of features of data representing a concentration of food allergen contained is the food sample; and outputs allergen concentration data. | 2010-09-02 |
20100222225 | Microarray-Based Gene Copy Number Analyses - This invention contemplates an accurate and efficient estimation of gene copy number using oligonucleotide microarrays. The method integrates gene copy number data obtained from perfect match and mismatch probe sequence structure intensities and probe binding affinities. In one embodiment, an accurate determination of single nucleotide polymorphisms (SNPs) sequences is obtained. In another embodiment, an accurate detection and determination of DNA copy number alteration is obtained. In another embodiment, an accurate estimation for RNA gene expression is obtained. | 2010-09-02 |
20100222226 | Biochip - To provide an electronic component mounting system and an electronic component mounting method which can prevent a mounting failure due to positional error in a height direction of a substrate and ensure mounting quality. The electronic component mounting system includes a plurality of electronic component mounting devices connected to one another and mounts an electronic component on a substrate to manufacture a mounting substrate. A print test device for testing the substrate after solder printing measures a height position of a height measurement point set on the upper surface of the substrate | 2010-09-02 |
20100222227 | RAPID GENOTYPING ANALYSIS AND THE DEVICE THEREOF - The present invention describes methods of performing rapid nucleic acid detection using a flow through process. The methods comprise single-step signal amplification and/or a one-step hybridization protocol. Using the flow through hybridization process, the present invention provides a more efficient, faster and less expensive genotyping method. This invention further provides a Single Nucleotide Polymorphism (SNP)-based DNA fingerprinting method for rapid and accurate genotyping, identification as well as DNA analyses of genetic materials from human beings and other different organisms. In addition this invention also discloses devices for rapid and sensitive analysis of target analysts. | 2010-09-02 |
20100222228 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING IRRITABLE BOWEL SYNDROME - The present invention relates generally to therapy and diagnosis of disorders associated with chronic visceral hypersensitivity (CVH), and in particular irritable bowel syndrome (IBS). In particular, this invention relates to the polypeptides as well as to the polynucleotides encoding these polypeptides, wherein said polypeptides are shown to be associated with CVH. These polypeptides and polynucleotides are useful in the diagnosis, treatment and/or prevention of disorders associated with CVH, in particular in the diagnosis, treatment and/or prevention of disorders associated with IBS. | 2010-09-02 |
20100222229 | Gene Expression Markers for Breast Cancer Prognosis - The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer. | 2010-09-02 |
20100222230 | DIAGNOSTIC AND PROGNOSTIC METHODS FOR RENAL CELL CARCINOMA - The present invention provides methods for diagnosis and prognosis of renal cell carcinoma (RCC) using expression analysis of one or more groups of genes, and a combination of expression analysis from a biological sample from the subject. The methods of the invention provide a method for superior detection accuracy for RCC as compared to any other currently available method for RCC diagnostic or prognosis. The invention also provides kits for diagnosis and prognosis of RCC using expression analysis. | 2010-09-02 |
20100222231 | USE OF ANTISENSE OLIGONUCLEOTIDE LIBRARIES FOR IDENTIFYING GENE FUNCTION - A method for identifying one or more genes involved in a phenotype of cells, tissues or organisms, comprising the steps of contacting cells, tissues or organisms which exhibit the phenotype with a library of antisense oligonucleotides and performing a primary phenotypic assay to determine which antisense oligonucleotides in the library attenuate the phenotype. These antisense oligonucleotides correspond to genes involved in the phenotype. The method may be used to identify genes involved in various disease states. | 2010-09-02 |
20100222232 | ENRICHMENT AND SEQUENCE ANALYSIS OF GENOMIC REGIONS - The present invention provides novel methods for reducing the complexity of preferably a genomic sample for further analysis such as direct DNA sequencing, resequencing or SNP calling. The methods use pre-selected immobilized oligonucleotide probes to capture target nucleic acid molecules from a sample containing denatured, fragmented (genomic) nucleic acids for reducing the genetic complexity of the original population of nucleic acid molecules. | 2010-09-02 |
20100222233 | AFFINITY CAPTURE OF PEPTIDES BY MICROARRAY AND RELATED METHODS - The invention provides methods of detecting polypeptides in a sample. The method can include the steps of cleaving polypeptides in a test sample to generate peptides; adding a predetermined amount of isotopically labeled peptide standards to the cleaved test sample, wherein the peptide standards correspond to peptides cleaved with the same reagent used to cleave the test sample; contacting the cleaved test sample containing peptide standards with an array of immobilized binding agents specific for the peptide standards; washing the array to remove unbound peptides, thereby retaining affinity captured sample peptides and standard peptides; analyzing the affinity captured peptides using mass spectrometry; and determining the presence of bound test peptides and standard peptides. The method can further include the step of quantifying the amount of the test peptides by comparing the ratio of test peptide to corresponding standard peptide. | 2010-09-02 |
20100222234 | Malaria antigen screening method - The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo. | 2010-09-02 |
20100222235 | High throughput screening methods for fuel compositions - Methods for determining deposit formation tendencies for a plurality of fluid samples of different compositions is provided. Each sample includes fuel additive compositions containing one or more fuel additives or fuel compositions containing one or more fuels and one or more fuel additives. The methods can advantageously be optimized using combinatorial chemistry, in which a database of combinations of fuel compositions are generated. As market conditions vary and/or product requirements or customer specifications change, conditions suitable for forming desired products can be identified with little or no downtime. | 2010-09-02 |
20100222236 | MULTIPLE ANTIGENIC PEPTIDE ASSAY FOR DETECTION OF HIV OR SIV TYPE RETROVIRUSES - A method for detecting at least one antibody directed against at least one primate immunodeficiency virus in a biological sample that includes contacting a biological sample with (i) at least one detection multiple antigenic peptide comprising a portion of an immunodominant region of a transmembrane protein of a primate immunodeficiency virus and (ii) at least one differentiation multiple antigenic peptide comprising a portion of a V3-loop of an envelope protein of a primate immunodeficiency virus. Also disclosed is an enzyme immunoassay that includes a first substrate to which are bound at least one of the detection multiple antigenic peptides and a second substrate to which are bound at least one of the differentiation multiple antigenic peptides. | 2010-09-02 |
20100222237 | Methods for Generating Polynucleotides Having Desired Characteristics by Iterative Selection and Recombination - A method for DNA reassembly after random fragmentation, and its application to mutagenesis of nucleic acid sequences by in vitro or in vivo recombination is described. In particular, a method for the production of nucleic acid fragments or polynucleotides encoding mutant proteins is described. The present invention also relates to a method of repeated cycles of mutagenesis, shuffling and selection which allow for the directed molecular evolution in vitro or in vivo of proteins. | 2010-09-02 |
20100222238 | Asymmetrical Adapters And Methods Of Use Thereof - A pair of asymmetrical, partially double-stranded oligonucleotide adapters are provided wherein the pair of adapters comprise a first asymmetrical oligonucleotide adapter comprising a single-stranded 3′ overhang and a second asymmetrical double-stranded oligonucleotide adapter comprising a single-stranded 5′ overhang and at least one blocking group on the strand of said second asymmetrical oligonucleotide adapter that does not comprise the 5′ overhang. Also provided are a pair of double-stranded Y oligonucleotide adapters and a pair of double-stranded bubble oligonucleotide adapters and methods of using said asymmetrical adapters for amplification of at least one double stranded nucleic acid molecule, wherein the amplification produces a plurality of amplified nucleic acid molecules having a different nucleic acid sequence at each end are also described. Also provided is a method for exponentially amplifying one strand in a double-stranded nucleic acid molecule. Also provided are methods for preparing libraries of paired tags using COS-linkers. Also provided are cleavable adapters comprising an affinity tag and a cleavable linkage, wherein cleaving the cleavable linkage produces two complementary ends. Methods of using the cleavable adapters to produce a paired tag library are also described. | 2010-09-02 |
20100222239 | COMPOSITIONS CONTAINING AMIDE SURFACTANTS AND METHODS FOR INHIBITING THE FORMATION OF HYDRATE AGGLOMERATES - One or more compositions and methods for inhibiting the formation of hydrate agglomerates in a fluid comprising water, gas, and optionally liquid hydrocarbon are disclosed. The fluid can be contained in an oil or gas pipeline or refinery. | 2010-09-02 |
20100222240 | Wellbore Servicing Fluids Comprising Grafted Homopolymers and Methods of Using Same - A non-aqueous wellbore servicing fluid comprising an alpha-olefin homopolymer grafted with a polar monomer. | 2010-09-02 |
20100222241 | Clay Inhibitors for the Drilling Industry - The inhibition of hydration of clays in drilling operations may be accomplished using an aqueous based drilling fluid containing from 0.2 to 5 wt % of 1,2-cyclohexanediamine and/or its salts. | 2010-09-02 |
20100222242 | PERACID OIL-FIELD VISCOSITY BREAKER AND METHOD - Aqueous well treatment fluid compositions are disclosed comprising an aqueous fluid containing polymer or copolymer for modifying fluid viscosity of the aqueous fluid and, in addition, an agent for effecting a controlled reduction in the aqueous fluid viscosity in a subterranean environment. The viscosity-reducing agent comprises a dilute concentration of peracetic acid. A method of using such compositions in oil- and gas-field treatment operations is also disclosed. | 2010-09-02 |
20100222243 | Porous Particulate Materials and Compositions Thereof - Methods and compositions useful for subterranean formation treatments, such as hydraulic fracturing treatments and sand control that include porous materials. Such porous materials may be selectively configured porous material particles manufactured and/or treated with selected glazing materials, coating materials and/or penetrating materials to have desired strength and/or apparent density to fit particular downhole conditions for well treating such as hydraulic fracturing treatments and sand control treatments. Porous materials may also be employed in selected combinations to optimize fracture or sand control performance, and/or may be employed as relatively lightweight materials in liquid carbon dioxide-based well treatment systems. | 2010-09-02 |
20100222244 | LUBRICATING COMPOSITIONS BASED ON PERFLUOROPOLYETHERS - Use as additive to stabilize perfluoropolyether lubricant oils at high temperatures, preferably higher than 200° C., of a solid polymer at room temperature, having a softening or a melting point higher than 150° C., preferably higher than 200° C., and containing in the repeating unit at least one aromatic ring; preferably in the backbone, and lubricating compositions containing said additive. | 2010-09-02 |
20100222245 | Tartaric Acid Derivatives as Fuel Economy Improvers and Antiwear Agents in Crankcase Oils and Preparations Thereof - Formulations using tartaric compounds of the present invention in a low sulfur, low ash and low phosphorous lubricant lower wear, and friction and improves fuel economy. | 2010-09-02 |
20100222246 | SKIN OR HAIR WASHING COMPOSITION - A skin or hair washing composition having excellent foamability and a good feeling upon use in the process from washing to after drying, is provided. | 2010-09-02 |
20100222247 | Cleaning Agent - Liquid, low-alkaline and bleach-free dishwasher detergent having a pH value (20° C.) of 8 to 12 and containing: a) 10 to 60 percent by weight of a builder; b) more than 1.5 percent by weight of a phosphonate; c) 0.1 to 20 percent by weight of an anionic copolymer comprising: i) unsaturated carboxylic acid(s) and ii) sulfonic acid group-containing monomer(s). Detergents according to the invention exhibit a good cleaning power on bleachable dirt, particularly tea stains. | 2010-09-02 |
20100222248 | CLEANING COMPOSITION FOR METAL SURFACES - The invention relates to an aqueous alkaline cleaning composition for cleaning metal surfaces, containing at least one non-ionic surfactant having demulsifying action and based on ethoxylated alkyl alcohols having one or two alkyl groups, each comprising an average of 7.5 to 16.5 carbon atoms, and an average of 5.5 to 18.5 EO groups per alkyl group, and comprising an end group closure or two end group closures, of which at least one end group closure is an isopropyl, isobutyl, tertiary butyl and/or benzyl group, wherein the surfactant is not propoxylated. | 2010-09-02 |
20100222249 | Liquid Detergent Composition - A composition comprising a liquid portion comprising at least one surfactant, at least one suspending agent, and at least one viscosity control agent, wherein the composition has an apparent viscosity under a shear stress of 0.5 Pa of at least about 1,000 Pa·s; and the composition has an apparent viscosity under a shear stress of 100 Pa of less than about 10 Pa·s. The composition is capable of suspending materials, but it still has desired rheological properties. | 2010-09-02 |
20100222250 | POLY-BETA-PEPTIDES FROM FUNCTIONALIZED BETA-LACTAM MONOMERS AND ANTIBACTERIAL COMPOSITIONS CONTAINING SAME - Disclosed is a method of making β-polypeptides. The method includes polymerizing β-lactam-containing monomers in the presence of a base initiator and a co-initiator which is not a metal-containing molecule to yield the product β-polypeptides. Specifically disclosed are methods wherein the base initiator is potassium t-butoxide, lithium bis(trimethylsilyl)amide (LiN(TMS) | 2010-09-02 |
20100222251 | MIXTURE COMPRISING AN AMYLIN PEPTIDE AND A PROTRACTED INSULIN - The invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide and a protracted insulin peptide. | 2010-09-02 |
20100222252 | DESHYDROXY VANCOMYCIN, THE PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE - The present invention provides a deshydroxy vancomycin compound,a method of its preparation and a pharmaceutical composition comprising a pharmaceutically effective amount of the deshydroxy vancomycin and the use of the said composition in the preparation of drugs for the treatment of susceptible bacteria infections. The method includes the following steps: (1) preparing a concentrated vancomycin solution containing the deshydroxy vancomycin by fermentations of | 2010-09-02 |
20100222253 | METHODS FOR EXTRACTING PLATELETS AND COMPOSITIONS OBTAINED THEREFROM - This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same. | 2010-09-02 |
20100222254 | STABILIZATION OF CLOSTRIDIUM BOTULINUM NEUROTOXIN COMPLEX - A stable composition including a non-covalent complex of a botulinum neurotoxin and a cyclodextrin and a method of preserving botulinum neurotoxin and for producing a botulinum neurotoxin composition with improved stability properties in an efficient and economically advantageous manner. The invention seeks to alleviate the problems associated with rapid degradation or denaturation of botulinum neurotoxin by providing a novel composition that exhibits improved stability properties. The botulinum neurotoxin is preferably stabilized by forming a cyclodextrin complex. | 2010-09-02 |
20100222255 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME - Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: | 2010-09-02 |
20100222256 | Novel polypeptide anti-HIV agent containing the same - The present invention provides novel polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like), and methods of using same in the treatment of HIV. | 2010-09-02 |
20100222257 | SUBSTITUTED PHENETHYLAMINES - Disclosed herein are substituted phenethylamine alpha adrenergic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 2010-09-02 |
20100222258 | TNF antagonist and TNF inhibitor containing it as an effective ingredient - The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient. | 2010-09-02 |
20100222259 | Compositions for enhancing the production of PPAR and/or PPAR-associated factors - The present inventors focused on certain nutritional compositions known to have activity of controlling blood glucose levels. These foods were administered to rats for long periods, and real-time PCR was used to analyze the expression of genes associated with lipid metabolism in the liver and adipose tissues. As a result, the present inventors found that the expression of the PPARα gene is enhanced by these foods, and that this is accompanied by suppressed expression of fatty acid synthase and enhanced expression of a group of PPARα target genes associated with fatty acid metabolism. The present inventors also confirmed the effect of these foods in enhancing the expression of PPARγ and adiponectin, and discovered that these foods have the activity of enhancing the production of PPAR and PPAR-associated factors. | 2010-09-02 |
20100222260 | Uses of pegylated albumin - The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutically effective amount of a PEGylated albumin. | 2010-09-02 |
20100222261 | PEPTIDIC ANTAGONISTS OF CLASS III SEMAPHORINS/NEUROPILINS COMPLEXES - The present invention concern a peptidic antagonist of class III semaphorins/neuropilins complexes comprising an amino acid sequence, which is derived from the transmembrane domain of a protein selected in the group consisting of neuropilin-1, neuropilin-2, plexin-A1, plexin-A2, plexin-A3, plexin-A4, Nr-CAM, L1-CAM, integrin Beta 1 and integrin beta 2, and including at least a GxxxG motif, eventually fused to an heterologous sequence; a nucleic acid encoding for said peptidic antagonist, a pharmaceutical composition comprising such a peptidic antagonist or a nucleic acid encoding thereof and uses thereof. | 2010-09-02 |
20100222262 | SUBSTITUTED 1, 3-CYCLOPENTADIONE ATTENUATED ENDOTHELIAL INFLAMMATION AND ENDOTHELIAL-MONOCYTE INTERACTIONS - Compositions and methods for reducing cardiovascular risk utilizing substituted 1,3-cyclopentadione compounds are described. | 2010-09-02 |
20100222263 | ATAP PEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND ASSOCIATED METHODS OF USE - Disclosed herein are nucleic acid sequences that encode pro-apoptotic polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of proliferative disorders and bacterial infections using the nucleic acids and proteins of the invention. | 2010-09-02 |
20100222264 | USE OF RGD-ENRICHED GELATINE-LIKE PROTEINS FOR INHIBITION OF CANCER METASTASIS - The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif. Preferably the RGD-enriched gelatines arc prepared by recombinant technology, and have a sequence that is derived from a human gelatine or collagen amino acid sequence. The invention also relates to RGD-enriched gelatines that are used for attachment to integrins. In particular The RGD-enriched gelatines of the invention are suitable for coating a cell culture support for growing anchor-dependant cell types. Further, the RGD-enriched gelatines of the invention may find use in medical applications, in particular as a coating on implant or transplant material or as a component of drug delivery systems. | 2010-09-02 |
20100222265 | HEPARIN BINDING EPIDERMAL GROWTH FACTOR (HB-EGF) FOR USE IN METHODS OF TREATING AND PREVENTING INTESTINAL INJURY RELATED TO HEMORRHAGIC SHOCK AND RESUSCITATION - The invention is related to methods of protecting, preventing and reducing intestinal injury in a human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation (HS/R) comprising administering heparin binding epidermal growth factor (HB-EGF). The invention is also related to methods of inhibiting deterioration of intestinal blood flow and methods of preserving and increasing intestinal blood flow by administering HB-EGF to a human subject. In addition, the methods of the invention should improve the clinical outcome of human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation. | 2010-09-02 |
20100222266 | A METHOD OF USING INTERFERON-LIKE PROTEIN ZCYTO21(IL-29) TO TREAT HEPATITIS B - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-a at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 2010-09-02 |
20100222267 | RECOMBINANT TRANSFERRIN MUTANTS - The present invention provides a recombinant protein comprising the sequence of a transferrin mutant, wherein Ser415 is mutated to an amino acid which does not allow glycosylation at Asn413 and/or wherein Thr613 is mutated to an amino acid which does not allow glycosylation as Asn611. It also provides polynucleotides encoding the same and methods of making and using said recombinant protein. | 2010-09-02 |
20100222268 | ANTIBIOTIC PEPTIDES - This invention concerns novel antibiotic peptide and peptide derivates, especially for use in medicine. Further, the invention relates to compositions and methods for killing microbes, like bacteria or fungus, and methods to treat microbial infections. The invention further relates to a method for drug screening analysis. The peptides and peptide derivates have the general formula Sub | 2010-09-02 |
20100222269 | IMPROVED DERIVATIVES OF AMYLIN - The invention relates to derivatives of human amylin or analogues thereof which bind to the amylin receptor and are linked to an albumin binding compound, pharmaceutical compositions comprising these derivatives and methods for obtaining such. | 2010-09-02 |
20100222270 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS - This application relates to a compound of Formula ! (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an antagonist of receptor CRTH2, as well as a process for its preparation and intermediates therefor. | 2010-09-02 |
20100222271 | Formulation to Improve Gastrointestinal Function - The subject invention provides compositions, and uses thereof, that improve gastrointestinal function. The compositions and methods of the subject invention are particularly advantageous for use with neonates because they can be used to stimulate development of the immature intestine in order to provide an enhanced ability to absorb nutrients and attain a stronger barrier function. | 2010-09-02 |
20100222272 | Pharmaceutical Compositions for the Treatment of TNF-Alpha Related Disorders - The invention relates to a pharmaceutical composition comprising a variant TNF-α protein that inhibits the activity of soluble TNF-α while substantially maintaining the activity of transmembrane TNF-α, a buffer, and a tonicity agent, wherein said composition has a pH from approximately 5.0 to 8.0. | 2010-09-02 |
20100222273 | MODIFIED CRY35 PROTEINS - This invention provides modified, insecticidal Cry35 proteins with enhanced properties as compared to wild-type Cry35 proteins. The modifications to these proteins were based in part on analysis of the atomic coordinates and three-dimensional (3D) structure of the ˜45 kDa 149B1 protein and other proteins in the Cry35 class. The subject invention also includes polynucleotides that encode these modified proteins, and transgenic plants that produce these modified proteins. This invention further provides methods of controlling plant pests, including rootworms, with these modified proteins. The modified proteins of the subject invention include chimeric toxins involving exchanged segments, domains, and motifs as discussed herein. The subject invention also provides methods of modifying Cry35 proteins. | 2010-09-02 |
20100222274 | GLYCOSYLATION-DEFICIENT HEPATOCYTE GROWTH FACTOR - The invention provides a modified glycosylation-deficient HGF and a production method thereof. The glycosylation-deficient HGF is produced by introducing amino acid mutation(s) so that no glycosylation take place at at least one glycosylation site of hepatocyte growth factor. | 2010-09-02 |
20100222275 | THERAPEUTIC AGENT FOR VITILIGO AND METHOD OF ACCELERATING PIGMENTATION - Provided are a pharmaceutical product capable of treating vitiligo by thickening the epidermis at a vitiligo-affected site, which has been thinned, to thereby accelerate pigmentation, and a method of accelerating pigmentation by thickening the epidermis. | 2010-09-02 |
20100222276 | PROTEASE-SENSITIVE SITE IN APOLIPOPROTEIN A1, THERAPEUTIC AND DIAGNOSTIC IMPLICATIONS - The invention relates to the identification of a naturally occurring internal proteolytic cleavage site in the ApoA1 protein, which leads to inactivation of the mature protein. Specific modification of this cleavage site leads to a stabilised ApoA1 protein, which is beneficial for the reverse cholesterol transport. The invention therefore encompasses pharmaceutical compositions comprising a recombinant stabilised variant ApoA1 protein or rHDL particles comprising such a protein, for use in the treatment of patients having reduced HDL or hampered reverse cholesterol transport. | 2010-09-02 |
20100222277 | Regulation of Food Preference Using GLP-1 Agonists - GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono- and di-saccharides together constitute a large proportion of the total amount of carbohydrates. | 2010-09-02 |
20100222278 | USE OF LEPTIN FOR THE PREVENTION OF EXCESS BODY WEIGHT AND COMPOSITION CONTAINING LEPTIN - The invention relates to the use of leptin in the preparation of an ingestible composition for children from nursing infants to adolescents, comprising leptin at a concentration greater than 50 ng/kg for the prevention of excess weight and/or the complications associated therewith. The invention comprises the use of a fully- or partially-hydrolyzed recombinant leptin. Said ingestible composition is a supplement for developmental nutrition, contains between 0.1 and 30 micrograms/liter leptin, provides a daily dose of leptin of more than 25 ng and can take the form of a solid, i.e. a tablet, capsule or reconstitutable powder, or a liquid, i.e. a syrup or drink. | 2010-09-02 |
20100222279 | COMPOSITION FOR ANIMAL CONSUMPTION AND METHOD FOR REDUCING MAP KINASE ACTIVITY - This invention is directed generally to compositions (including foods nutritional supplements, treats, and toys) for animal consumption, particularly compositions that comprise omega-3 and omega-6 polyunsaturated fatty acids, and particularly compositions that tend to aid in reducing mitogen-activated-protein (“MAP”) kinase activity in animals. This invention also is directed generally to methods for using such compositions, particularly to methods for using such compositions to reduce MAP kinase activity in animals, and particularly to methods for using such compositions to treat a cancer or tissue hyperplasia. This invention is further directed generally to processes for making such compositions. | 2010-09-02 |
20100222280 | PEPTIDES WITH THE CAPACITY TO BIND TO TRANSFORMING GROWTH FACTOR beta 1 (TGF-beta 1) - The described peptides possess the capacity to bind to Transforming Growth Factor TGF-β1 (TGF-β1), and are potential inhibitors of the biological activity of TGF-β1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-β1 expression, e.g., liver fibrosis, pulmonary fibrosis, corneal fibrosis and haze. | 2010-09-02 |
20100222281 | DELIVERY OF HYDROPHILIC DRUGS - Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain. | 2010-09-02 |
20100222282 | METHOD OF DIAGNOSIS AND METHOD OF TREATMENT - The present invention relates to a method for diagnosing higher susceptibility for diseases and conditions associated with low levels of AKG in a human or animal comprising the following steps: a) obtaining a biological sample from said human or animal; b) measuring the alpha-ketoglutaric acid (AKG) level in the biological sample; and c) comparing said measured AKG level with normal average AKG levels, wherein a level of AKG in said sample lower than an average level is indicative of a higher susceptibility for various diseases. Further the invention relates to a use of a substance comprising at least one member selected from the group consisting of AKG and derivates, metabolites, analogues or salts thereof for the manufacture of a pharmaceutical preparation or a food or feed supplement for the treatment or prophylaxis of diseases and conditions associated with low levels of AKG in a human or animal with low levels of AKG compared with normal average AKG levels. | 2010-09-02 |
20100222283 | USE OF GAMMA SECRETASE INHIBITORS AND NOTCH PATHWAY INHIBITORS FOR TREATMENT AND PREVENTION OF RENAL DESEASE - Methods are provided for treating and preventing renal disease in a subject by administering a gamma secretase inhibitor or a Notch pathway inhibitor to the subject. | 2010-09-02 |
20100222284 | COMPOSITION FOR INHIBITING THE ONSET OF ARTERIOSCLEROSIS AND INHIBITION METHOD - [Object] To provide a composition for inhibiting the onset of arteriosclerosis by using a rare sugar D-psicose and a method of inhibiting the onset of arteriosclerosis. | 2010-09-02 |
20100222285 | METHOD OF CONTROLLING THE PROLIFERATION OF VASCULAR ENDOTHELIAL CELLS AND INHIBITING LUMEN FORMATION - A specific rare sugar having effects of inhibiting the proliferation of vascular endothelial cells and lumen formation is disclosed. This rare sugar is provided as a preventive/remedy for diseases with angiogenesis, a cosmetic or a functional food. The proliferation of vascular endothelial cells is controlled utilizing the vascular endothelial cell proliferation-controlling effect of D-mannose, D-allose, 2-deloxy-D-glucose, 3-deoxy-D-glucose, L-sorbose, 2-deoxy-D-ribose and/or 2-deoxy-L-ribose. Lumen formation of vascular endothelial cells is inhibited by utilizing the vascular endothelial cell lumen formation-inhibiting effect of D-allose, D-altrose, D-glucose, D-talose, L-allose, 2-deloxy-D-glucose, 3-deoxy-D-glucose, D-ribose, L-ribose, 2-deoxy-D-ribose and/or 2-deoxy-L-ribose. | 2010-09-02 |
20100222286 | RECEPTOR MODULATORS EXHIBITING NEUROPROTECTIVE AND MEMORY ENHANCING ACTIVITIES - The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, methods of enhancing the brain's cognitive functions and methods of treating depression, anxiety and cachexia induced by a chronic disease in mammals and humans. | 2010-09-02 |
20100222287 | Therapeutic Cancer Treatments - Provided are methods for treating prostate cancer by administering a therapeutically effective amount of a hedgehog inhibitor. | 2010-09-02 |
20100222288 | Stabilized Formulation of Ivermectin Feed Premix with an Extended Shelf Life and Method of Making the Same - The invention relates to a stabilized premix feed or feed-like formulation that has an extended shelf life due to a decrease of the degradates of the active ingredient by controlling the amount of an already existing stabilizer in the formulation. The feed premix is used in the treatment or prophylaxis of parasites in mammals, in particular swine and horses. The invention further relates to a method to extend the shelf life of a stable premix feed or feed-like formulation for the treatment or prophylaxis of parasite infestation in swine and horses comprising controlling the amount of an already existing antioxidant or stabilizer in the formulation to decrease or to prevent the formation of acid/base catalyzed decomposition of the active ingredient. | 2010-09-02 |
20100222289 | METHODS FOR DIAGNOSIS AND TREATMENT OF CHRONIC FATIGUE SYNDROME - Methods for diagnosing and treating chronic fatigue syndrome in a patient comprise, for example, testing tissue of the patient for the presence of nucleic acid molecules of one or more CFS-causing herpesviruses and one or more non-herpesvirus infectious agents, and diagnosing the patient's CFS as (a) caused by one or more herpesvirus and no non-herpesvirus infectious agent; (b) caused by one or more herpesviruses and at least one non-herpesvirus infectious agent; (c) not caused by a herpesvirus and caused by at least one non-herpesvirus infectious agent; and (d) not caused by a herpesvirus and not caused by at least one non-herpesvirus infectious agent. In some embodiments, the methods of treating comprise administering a therapeutically effective amount of at least one pharmaceutical composition for each herpesvirus and/or non-herpesvirus infectious agent present found in the patient. | 2010-09-02 |
20100222290 | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics - Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. | 2010-09-02 |
20100222291 | MEDICINAL FORMS OF PHOSPHOLIPID PREPARATIONS AND METHODS FOR THEIR PREPARATION - A method for producing an encapsulated medicinal form of a combination of phospholipid and glycyrrhizic acid or a pharmaceutically acceptable salt thereof, said method comprising mixing a solution of phospholipid in an organic solvent with glycyrrhizic acid or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier substance or additive, granulating the resultant mixture, and encapsulating the resultant product, for example after grinding with a pharmaceutically acceptable carrier substance or additive. Products obtained by this method form a further aspect of the invention, and are useful in the treatment or prevention of diseases associated with liver disorders. | 2010-09-02 |
20100222292 | METHOD FOR TRANSDIFFERENTIATION OF BODY TISSUES - The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune diseases. | 2010-09-02 |
20100222294 | Formulations of ATP and Analogs of ATP - This disclosure provides solutions and compositions (e.g., pharmaceutical solutions and compositions) containing adenosine 5′-triphosphate (ATP) or an analog thereof. In addition, it features methods of making and using the solutions and compositions. | 2010-09-02 |
20100222295 | Anti-Viral Pyrimidine Nucleoside Derivatives - A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH | 2010-09-02 |
20100222296 | PYRIMIDINES, SUCH AS URIDINE, IN TREATMENTS FOR PATIENTS WITH BIPOLAR DISORDER - The invention is based on the discovery that specific dosages of pyrimidine compositions, such as uridine compositions, can be used to treat patients diagnosed with bipolar disorder. | 2010-09-02 |
20100222297 | CELL WALL DERIVATIVES, THEIR PREPARATION PROCESS, AND USE THEREOF - In a first aspect, the present invention relates to a method for isolating cell wall derivatives from fungal or yeast biomass. According to this method, chitin polymers or chitin-glucan copolymers can be obtained. In another aspect, the invention relates to a method for preparing chitosan from chitin. The invention further relates to chitin polymers, chitin-glucan polymers and chitosan polymers obtainable by the methods according to the invention. Moreover, the invention relates to the use of chitin polymers, chitin-glucan copolymers or chitosan polymers obtainable by the method according to the present invention in medical, pharmaceutical, agricultural, nutraceutical, food, textile, cosmetic, industrial and/or environmental applications, and in particular of chitin-glucan copolymers used as a technological additive for treating a food-grade liquid or in orally administered compositions. | 2010-09-02 |
20100222298 | SPILL RESISTANT FORMULATIONS CONTAINING CLAYS - The invention relates to novel spill resistant formulations comprising either a weak base or a weak acid as the pharmaceutical ingredient, a liquid base, a clay and a water soluble cellulose ether. The clay and cellulose ether allow for a broader pH range into which the pharmaceutically active agent may be dispersed or dissolved, and therefore allows for easier preparation and formulation of the pharmaceutical composition. | 2010-09-02 |
20100222299 | COMPOUND - The present invention involves tetrahydroisoquinoline compounds and their use in the inhibition and/or prevention of tumor growth. | 2010-09-02 |
20100222300 | A2B Adenosine Receptor Antagonists - Disclosed are novel compounds that are A | 2010-09-02 |
20100222301 | TOPICAL DRUG FOR TREATMENT AND/OR PREVENTION OF DIABETIC NEUROPATHY, MICROANGIOPATHY AND DIABETIC AND NON DIABETIC ULCERS AND WOUND INFECTION - The various embodiments herein provide a topical drug composition for the treatment of diabetes-related complications. According to one embodiment herein, the composition comprises of a compound belonging to a group of chemicals containing borates. Boric acid is used as the base material of the drug. Boric acid is dissolved in saline 0.9% or half saline serum or water, distilled water or boiled water to obtain a boric acid solution with given concentration. The best concentration is 3-5% solution. Alcohol at preset concentration is added to the boric acid solution. According to another embodiment, a method is provided for preparing a topical drug composition for the treatment of diabetes-related disorders. | 2010-09-02 |